Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil

DSpace/Manakin Repository

Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil

Citable link to this page

 

 
Title: Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil
Author: Cardoso, Sandra W; Luz, Paula M; Velasque, Luciane; Torres, Thiago; Coelho, Lara; Freedberg, Kenneth A; Veloso, Valdilea G; Walensky, Rochelle P; Grinsztejn, Beatriz

Note: Order does not necessarily reflect citation order of authors.

Citation: Cardoso, Sandra W, Paula M Luz, Luciane Velasque, Thiago Torres, Lara Coelho, Kenneth A Freedberg, Valdilea G Veloso, Rochelle P Walensky, and Beatriz Grinsztejn. 2014. “Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.” AIDS Research and Therapy 11 (1): 29. doi:10.1186/1742-6405-11-29. http://dx.doi.org/10.1186/1742-6405-11-29.
Full Text & Related Files:
Abstract: Background: While Brazil has had a long-standing policy of free access to antiretroviral therapy (ART) for all in need, the epidemiological impact of ART on human immunodeficiency virus (HIV) RNA suppression in this middle-income country has not been well evaluated. We estimate first-line ART effectiveness in a large Brazilian cohort and examine the socio-demographic, behavioral, clinical and structural factors associated with virologic suppression. Methods: Virologic suppression on first-line ART at 6, 12, and 24 months from start of ART was defined as having a viral load measurement ≤400 copies/mL without drug class modification and/or discontinuation. Drug class modification and/or discontinuation were defined based on the class of a particular drug. Quasi-Poisson regression was used to quantify the association of factors with virologic suppression. Results: From January 2000 through June 2010, 1311 patients started first-line ART; 987 (75%) patients used NNRTI-based regimens. Virologic suppression was achieved by 77%, 76% and 68% of patients at 6, 12 and 24 months, respectively. Factors associated with virologic suppression at 12 months were: >8 years of formal education (compared to <4 years, risk ratio (RR) 1.13, 95% confidence interval (95% CI) 1.03-1.24), starting ART in 2005-2010 (compared to 2000-2004, RR 1.25 95% CI 1.15-1.35), and clinical trial participation (compared to no participation, RR 1.08 95% CI 1.01-1.16). Also at 12 months, women showed less virologic suppression compared to heterosexual men (RR 0.90 95% CI 0.82-0.99). For the 24-month endpoint, in addition to higher education, starting ART in the later period, and clinical trial participation, older age and an NNRTI-based regimen were also independently associated with virologic suppression. Conclusions: Our results show that in Brazil, a middle-income country with free access to treatment, over three-quarters of patients receiving routine care reached virologic suppression on first-line ART by the end of the first year. Higher education, more recent ART initiation and clinical trial participation were associated with improved outcomes both for the 12-month and the 24-month endpoints, suggesting that further studies are needed to understand what aspects relating to these factors lead to higher virologic suppression.
Published Version: doi:10.1186/1742-6405-11-29
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158765/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987245
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters